CARSON and Campbell1 reported that ``diphenylpyraline'' (1-methyl-piperidyl-4 benzhydryl ether) had marked in vitro antifungal action against a group of organisms, including Trichophyton rubrum, Microsporum gypseum, Microsporum lanosum, Epidermophyton floccosum, and Candida albicans. These authors enthusiastically suggested that clinical corroboration should be attempted. In response to this suggestion, a therapeutic trial was carried out.
Except for the use of microscopic and culture technics, such as the use of a standard Sabouraud agar culture medium, to check clinical diagnosis, the study was entirely clinical. The chemical, pharmacologic, and physiologic aspects of ``diphenylpyraline'' will not be discussed at this time. Studies of these aspects have been accomplished elsewhere, and the results are to be published.
The mode of administration of ``diphenylpyraline''2 was limited to topical application. The active agent was incorporated in two separate vehicles, the selection of which was guided by the physical state of the eruption. In wet, oozing,
SOKOLOFF O. CLINICAL EVALUATION OF "DIPHENYLPYRALINE" AS AN ANTIFUNGAL AGENT. AMA Arch Derm Syphilol. 1951;64(6):754–756. doi:10.1001/archderm.1951.01570120089008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: